Randomized Phase IIa Clinical Study of an Anti-αβ Monoclonal Antibody in Idiopathic Pulmonary Fibrosis
Overview
Authors
Affiliations
Mechanosignaling via Integrins: Pivotal Players in Liver Fibrosis Progression and Therapy.
Sharip A, Kunz J Cells. 2025; 14(4).
PMID: 39996739 PMC: 11854242. DOI: 10.3390/cells14040266.
Advances and challenges in kidney fibrosis therapeutics.
Abbad L, Esteve E, Chatziantoniou C Nat Rev Nephrol. 2025; .
PMID: 39934355 DOI: 10.1038/s41581-025-00934-5.
Progressive lung fibrosis: reprogramming a genetically vulnerable bronchoalveolar epithelium.
Bridges J, Vladar E, Kurche J, Krivoi A, Stancil I, Dobrinskikh E J Clin Invest. 2025; 135(1).
PMID: 39744946 PMC: 11684817. DOI: 10.1172/JCI183836.
Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis: The INTEGRIS-IPF Clinical Trial.
Lancaster L, Cottin V, Ramaswamy M, Wuyts W, Gisli Jenkins R, Scholand M Am J Respir Crit Care Med. 2024; 210(4):424-434.
PMID: 38843105 PMC: 11351797. DOI: 10.1164/rccm.202403-0636OC.
Pulmonary Fibrosis and Diabetes Mellitus: Two coins with the same face.
Mari Y, Fraix M, Agrawal D Arch Intern Med Res. 2024; 7(1):53-70.
PMID: 38576768 PMC: 10994216. DOI: 10.26502/aimr.0165.